Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Iambic Therapeutics Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and multiple art units. This distribution shows that every active matter in the portfolio is currently being reviewed by a different examiner in a different technical section of the patent office.
SHIAO, REI TSANG is designated as the busiest examiner, with 1 pending office action under their review. Given the total volume of active matters, each of the distinct examiners is responsible for a single case. This lack of concentration means that no single examiner has a dominant influence over the company's current prosecution efforts.
The presence of 3 distinct art units indicates a variety of technical focuses within the company's biotechnology filings. Practitioners should be prepared to navigate the specific procedural nuances of the various art units. Consistency in prosecution will depend on monitoring the progress of these separate tracks, as there is no overlap in the personnel reviewing the applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| PATEL, SAGAR S | 1 | 75.7% | +34.9% |
| PULLIAM, JOSEPH CONSTANTINE | 1 | 38.5% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17332951 | Systems and Methods for Determining Molecular Properties with Atomic-Orbital-Based Features | PULLIAM, JOSEPH CONSTANTINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18453798 | COMPOUNDS AND METHODS FOR MODULATING HER2 | PATEL, SAGAR S | 17d overdue |
| 17332951 | Systems and Methods for Determining Molecular Properties with Atomic-Orbital-Based Features | PULLIAM, JOSEPH CONSTANTINE | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1626 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18917796 | COMPOUNDS AND METHODS FOR MODULATING HER2 | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18453798 | COMPOUNDS AND METHODS FOR MODULATING HER2 | PATEL, SAGAR S | 1626 | §112DP | Final Rejection | 17d overdue | Pending | Aug 22, 2023 |
| 17332951 | Systems and Methods for Determining Molecular Properties with Atomic-Orbital-Based Features | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | May 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIambic Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Rei Tsang Shiao has the most, with 1 of Iambic Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
